LISATA THERAPEUTICS, INC.
LSTA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for LSTA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · LSTA
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of innovative therapies, with a current emphasis on certepetide in solid tumor trials and a cash position of $10.4M as of 2026-06-30.
Key risk: Clinical trial failure risk
BioSniper Score
Based on 5 of 6 signals
Market Cap
$15.2M
Cash Runway
12.0 moLead Asset
certepetide (Phase 1/Phase 2)Next Catalyst
Phase2_Start · Jan 1, 2030Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 3 clinical trials · 1 catalyst for LISATA THERAPEUTICS, INC..
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of innovative therapies, with a current emphasis on certepetide in solid tumor trials and a cash position of $10.4M as of 2026-06-30.
- Clinical-stage company dedicated to innovative therapeutics [sec_mda · as of 2026-03-12].
- Cash and equivalents of $10.4M as of 2026-06-30 [sec].
- No revenue reported; net loss of $2.9M for the period ending 2026-06-30 [sec].
- Certepetide is in ongoing global clinical trials for solid tumors [sec_mda · as of 2025-11-06].
- Two prior Phase 2 trials (NCT04614484, NCT05712356) were terminated [catalyst].
What works
- Ongoing clinical trials for certepetide in multiple solid tumor types and combination regimens suggest a broad potential therapeutic scope [sec_mda · as of 2025-11-06].
- The company maintains an intellectual property portfolio with out-licensing opportunities, which could provide non-dilutive funding or partnerships [sec_mda · as of 2025-11-06].
What to weigh
- No approved products or revenue, with a net loss of $2.9M in the latest quarter [sec].
- Two prior Phase 2 trials were terminated, raising questions about clinical execution or program viability [catalyst].
- Cash of $10.4M may be limited relative to the costs of ongoing and planned clinical development [sec].
From the filings
Quoted directly from source documents.
Company is clinical-stage and focused on innovative therapies.
“We are a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative the”
SEC MD&A · March 12, 2026
Certepetide is in ongoing global trials for solid tumors.
“certepetide is currently the subject of ongoing clinical trials being conducted globally in a variety of solid tumor types and in combination with several chemotherapy and immunotherapy anti-cancer regimens.”
SEC MD&A · November 6, 2025
Two Phase 2 trials were terminated.
“Status: Terminated.”
Catalysts
Catalyst timeline
- 2030-01-01 · Phase2_Start — A Phase 1b/2a, double-blind, placebo-controlled study evaluating a single int (likely a typo for 'intratumoral' or 'intravenous') is planned to start.
Risks & what to watch (4)›
Key risks
- Clinical trial failure risk — No guarantee clinical programs will succeed or gain regulatory approval [sec_mda · as of 2026-08-06].
- Limited cash runway — Cash of $10.4M may be insufficient to complete development without additional financing [sec].
- No revenue or approved products — Company has no revenue and relies on external funding for operations [sec].
- Terminated prior trials — Two Phase 2 trials were terminated, indicating potential setbacks [catalyst].
What to watch
- Progress of ongoing certepetide clinical trials in solid tumors [sec_mda · as of 2025-11-06].
- Cash burn rate and any future financing or partnership announcements [sec].
- Regulatory updates or milestones from the FDA or other agencies [sec_mda · as of 2026-08-06].
- Out-licensing or partnering deals for the intellectual property portfolio [sec_mda · as of 2025-11-06].
Sources: Catalysts · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run LISATA THERAPEUTICS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available LISATA THERAPEUTICS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
12.0 months
D/E 0.37 · 0% dilution
Lead: Phase 1/Phase 2
2 candidates
1 upcoming, next in ~1220d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
33
Total value held
$6.0M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 543,630 | $2.7M |
| renaissance technologies llc | 131,715 | $660K |
| deltec asset management llc | 90,000 | $451K |
| geode capital management, llc | 70,887 | $355K |
| css llc/il | 61,898 | $310K |
| blackrock, inc. | 54,857 | $275K |
| penderfund capital management ltd. | 47,500 | $238K |
| vanguard fiduciary trust co | 34,917 | $175K |
| gts securities llc | 31,396 | $157K |
| state street corp | 25,348 | $127K |
Showing top 10 of 33 institutional holders of LISATA THERAPEUTICS, INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 0.7%
- Days to cover
- 0.7
- Shares short
- 51,644
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
LSTA short interestGovernance
Frequently asked questions
What is the AI investment thesis for LISATA THERAPEUTICS, INC.?
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of innovative therapies, with a current emphasis on certepetide in solid tumor trials and a cash position of $10.4M as of 2026-06-30.
What is LISATA THERAPEUTICS, INC.'s lead drug candidate?
LISATA THERAPEUTICS, INC.'s most advanced tracked candidate is certepetide (Phase 1/Phase 2) for Cholangiocarcinoma; Pancreas Cancer.
What is LISATA THERAPEUTICS, INC.'s next catalyst?
LISATA THERAPEUTICS, INC.'s next tracked catalyst is a Phase2_Start event — "Phase 2 Start: A Phase 1b/2a, Double-blind, Placebo-controlled, Three Arm, Randomized Study Evaluating a Single Int" — expected January 1, 2030.
Who is the CEO of LISATA THERAPEUTICS, INC.?
Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D. is the chief executive officer of LISATA THERAPEUTICS, INC. (LSTA).
Where is LISATA THERAPEUTICS, INC. headquartered?
LISATA THERAPEUTICS, INC. (LSTA) is headquartered in Basking Ridge, NJ, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.